ReviewCell death discovery2020
An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer.
Review in Cell death discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Breast tumors interfere with endothelial TRAIL at the premetastatic niche to promote cancer cell seeding.Science advances · 2023Article
- Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries.Cell death and differentiation · 2023Review
- TRAIL promotes the polarization of human macrophages toward a proinflammatory M1 phenotype and is associated with increased survival in cancer patients with high tumor macrophage content.Frontiers in immunology · 2023Article
- Review
- TRAIL receptors promote constitutive and inducible IL-8 secretion in non-small cell lung carcinoma.Cell death & disease · 2022Article
- Endoplasmic reticulum-resident protein Sec62 drives colorectal cancer metastasis via MAPK/ATF2/UCA1 axis.Cell proliferation · 2022Article
- Extrinsic cell death pathway plasticity: a driver of clonal evolution in cancer?Cell death discovery · 2022Review
- Therapeutics Targeting the Core Apoptotic Machinery.Cancers · 2021Review
- Article
- Regulation of Cancer Metastasis by TRAIL/Death Receptor Signaling.Biomolecules · 2021Review
- Signaling pathways in intestinal homeostasis and colorectal cancer: KRAS at centre stage.Cell communication and signaling : CCS · 2021Review
- TRAIL receptor-induced features of epithelial-to-mesenchymal transition increase tumour phenotypic heterogeneity: potential cell survival mechanisms.British journal of cancer · 2021Review
- The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials.Frontiers in molecular biosciences · 2021Review
- Proteotoxic Stress and Cell Death in Cancer Cells.Cancers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 3 countries.
Funding
Abstract
Twenty-one percent of all human cancers bear constitutively activating mutations in the proto-oncogene
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.